Merck & Co.
As a leader in biopharmaceuticals, we focus on scientific innovation to deliver medicines and vaccines that may help millions of people around the world.
We’re a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies and animal health products. We’re focused on discovering new solutions for today and the future.
We aspire to be the premier research-intensive biopharmaceutical company. We’re at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
Explore Careers In
Our Therapeutic Areas:
We hold ourselves to the highest standards of ethics and integrity.
We’re driven by a desire to improve life
Our values represent the core of our character and guide every decision and action we take.
Patients first
Respect for people
Ethics and integrity
Innovation and scientific excellence
Don’t just join a company … find a sense of belonging! Our Employee Business Resource Groups (EBRGs) are voluntary, employee-led groups that aim to foster a diverse, inclusive work environment by supporting career development while providing culturally relevant insights that drive success. These groups and the people in them will provide a warm welcome to you.
Get to know us personally through employee spotlights, blogs and our podcast! Follow us on careers social for interview tips, resume tips, DEI, divisional information and more!
X | Facebook | Instagram | YouTube | Careers Blog | Career On Purpose Podcast
Blog Post
Sherif Chalifa, Business Analyst for Quality Systems
Sherif Chalifa, Business Analyst for Quality Systems
As I reflect on my time since joining Merck earlier this year, I am thrilled to say that it has been an excellent experience thus far.
Our Business
Our Business
Our Business
Make a change
Make a change
How we hire
How we hire
A decade of oncology advancements
A decade of oncology advancements
NEWS
In addition to massive layoffs – around 60% of its workforce – Yumanity also said it is considering “strategic alternatives” to its financial woes, including the possibility of selling or merging.
Although the Omicron surge appears to be waning in the U.S., the World Health Organization keeps an eye on four Omicron subvariants.
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended 14-1 that the two companies conduct a trial applicable to the U.S. population.
Merck has announced positive results from its Phase III KEYNOTE-522 study on the use of KEYTRUDA alongside chemotherapy in high-risk early-stage triple-negative breast cancer.
Here’s a look at five companies that produced non-vaccine treatments for COVID-19.
Antiviral pills against COVID-19 show promise for treating the disease, but they are not broadly accessible yet.
After reviewing available data, Bayer decided to abandon its Phase II development of eliapixant as the benefit-risk profile was not worthwhile.
The researchers believe Keytruda and possibly other anti-PD-1 checkpoint inhibitors might help the immune system track the last signs of HIV while also preventing HIV’s ability to hide.
JOBS
IN THE PRESS